Virtual screening targeting the conserved domain of the IAV M2 protein reveals the potential broad-spectrum anti-IAV activity of ajmaline
Biochemical and Biophysical Research Communications · 2026
DOI: 10.1016/j.bbrc.2026.153643 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2026. Verfasst von Min Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Guangxi Key Laboratory of Special Biomedicine, School of Medicine, Guangxi University, Nanning, China. Hauptthemen laut MEDLINE: Antiviral Agents, Viral Matrix Proteins, Influenza A virus. Die Arbeit nennt 34 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Guangzhou Municipal Science and Technology Program key projects, Guangxi University of Science and Technology.
Abstract (Originalsprache)
Influenza A virus (IAV) evolves rapidly through antigenic variation, leading to drug resistance and pandemic potential. To circumvent mutational escape, we employed a drug repurposing strategy targeting the evolutionarily conserved transmembrane domain (TMD) of the IAV M2 protein. Here, we report the discovery of Ajmaline, an antiarrhythmic alkaloid, as a broad-spectrum anti-IAV agent identified via virtual screening. Molecular docking and 100-ns dynamics simulations revealed stable binding across multiple IAV subtypes (H1N1, H2N2, H5N1, H7N9). The Cellular Thermal Shift Assay (CETSA) confirmed direct binding to both wild-type and N31S mutant M2 proteins. Ajmaline exhibited potent antiviral activity through dual mechanisms: direct inhibition of viral replication and upregulation of interferon-related genes (IFNB1, ISG56) coupled with suppression of apoptosis (Bax downregulation). In vivo, Ajmaline (15 mg/kg) improved survival to 83%, reduced pulmonary viral load, and alleviated lung pathology in H1N1-infected mice. These findings identify Ajmaline as a repurposed broad-spectrum antiviral candidate capable of overcoming existing drug resistance, providing a proof-of-concept for conserved-domain-targeting strategies in antiviral drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangxi Key Laboratory of Special Biomedicine, School of Medicine, Guangxi University, Nanning, China.
- Institute of Digestive Disease, Guangxi Academy of Medical Sciences, the People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
- Guangxi Key Laboratory of Special Biomedicine, School of Medicine, Guangxi University, Nanning, China. Electronic address: weipengcheng@gxu.edu.cn.
- Guangxi Key Laboratory of Special Biomedicine, School of Medicine, Guangxi University, Nanning, China. Electronic address: liukp@gxu.edu.cn.
- Guangxi Key Laboratory of Special Biomedicine, School of Medicine, Guangxi University, Nanning, China. Electronic address: sulan2021@gxu.edu.cn.
Förderung
- National Natural Science Foundation of China
- Guangzhou Municipal Science and Technology Program key projects
- Guangxi University of Science and Technology
Zitieren
APA
Chen, M., Chen, W., Jiang, X., Liang, S., Qin, Y., Tang, J., Li, Y., Wu, Q., Liang, X., Wei, P., Liu, K., & Luo, S. (2026). Virtual screening targeting the conserved domain of the IAV M2 protein reveals the potential broad-spectrum anti-IAV activity of ajmaline. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2026.153643
Vancouver
Chen M, Chen W, Jiang X, Liang S, Qin Y, Tang J, et al. Virtual screening targeting the conserved domain of the IAV M2 protein reveals the potential broad-spectrum anti-IAV activity of ajmaline. Biochemical and Biophysical Research Communications. 2026. doi:10.1016/j.bbrc.2026.153643
BibTeX
@article{Chen2026,
author = {Chen, Min and Chen, Wenhuan and Jiang, Xinyi and Liang, Shaomei and Qin, Yingqiao and Tang, Jiayi and Li, Yifei and Wu, Qifan and Liang, Xue and Wei, Pengcheng and Liu, Kunpeng and Luo, Sulan},
title = {Virtual screening targeting the conserved domain of the IAV M2 protein reveals the potential broad-spectrum anti-IAV activity of ajmaline},
journal = {Biochemical and Biophysical Research Communications},
year = {2026},
doi = {10.1016/j.bbrc.2026.153643}
}
EUVIMED